Status:
UNKNOWN
T-Cell Vaccination in Multiple Sclerosis (MS)
Lead Sponsor:
Sheba Medical Center
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
16-60 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety of T-cell vaccination in MS patients.
Detailed Description
Immunization of MS patients with irradiated autologous encephalitogenic myelin peptides (EMP) specific T-cell lines or clones. Clinical immunologic and neuroradiologic evaluation.
Eligibility Criteria
Inclusion
- Definite MS (post criteria)
- Relapsing remitting or primary progressive clinical course. At least one relapse in the last two years.
- Disease duration \> 1 year
- Expanded Disability Status Scale (EDSS) between 0-6
- Brain magnetic resonance imaging (MRI) compatible with MS
- Not involved in any other clinical trials
- No other systemic disease
Exclusion
- Does not comply with the above
Key Trial Info
Start Date :
July 1 1998
Trial Type :
INTERVENTIONAL
End Date :
December 1 2007
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00220428
Start Date
July 1 1998
End Date
December 1 2007
Last Update
January 24 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Sclerosis Center
Ramat Gan, Israel